GlassScriptPhysician profile
William A Dalrymple
NPI 1073909891
$2,301.41
in general payments reported to CMS, 2019-2025
10 companies · $479 in 2025
The $479 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,244 · 2022: $102 · 2024: $477 · 2025: $479.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $668 · Education: $287.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $668.35 |
| Education | $287.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic USA, INC. | $1,243.70 | 2019 | |
| Abbvie INC. | $233.68 | 2025 | |
| Csl Behring | $200.00 | 2024 | Kcentra |
| Neurocrine Biosciences, INC. | $157.84 | 2025 | |
| Abbott Laboratories | $124.75 | 2024 | Infinity |
| Kyowa Kirin, INC. | $101.87 | 2022 | |
| Medtronic, INC. | $99.14 | 2024 | Percept PC Brainsense |
| Teva Pharmaceuticals USA, INC. | $87.49 | 2025 | |
| Merz Pharmaceuticals, LLC | $31.77 | 2024 | Inbrija |
| Boston Scientific Corporation | $21.17 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dalrymple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.